<DOC>
	<DOCNO>NCT02996617</DOCNO>
	<brief_summary>Neutropenia one frequent adverse effect chemotherapy , main factor limit dosage continuation chemotherapy . The PEG-rhG-CSF increase plasma half-life , prolong efficacy compare rhG-CSF . The purpose study determine safety effectiveness PEG-rhG-CSF prevent neutropenia follow chemotherapy patient non-Hodgkin lymphoma .</brief_summary>
	<brief_title>PEG-rhG-CSF Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy Prevent Neutropenia</brief_title>
	<detailed_description>Neutropenia common clinical complication chemotherapy cancer patient . It important factor delay course standard treatment patient . Recombinant human granulocyte colony-stimulating factor ( rhG-CSF ) effective drug treatment chemotherapy-induced neutropenia . However , patient neutropenia , multiple rhG-CSF treatment usually require . This likely extend antitumor treatment period increase physical mental stress patient . Pegylated recombinant human granulocyte colony-stimulating factor ( PEG-rhG-CSF ) rhG-CSF chemically modify single methoxy polyethylene glycol group ; able alleviate neutropenia single dose . The aim present study determine safety effectiveness preventive treatment pegylated recombinant human granulocyte colony stimulate factor ( PEG-rhG-CSF ) concurrent chemotherapy-induced neutropenia provide rational basis clinical application . Therefore , investigator design multi-center , open-label , randomize control clinical study aim compare efficacy safety PEG-rhG-CSF rhG-CSF non-Hodgkin lymphoma receive chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Investigator diagnosis nonHodgkin lymphoma ( Highly invasive lymphoma/Burkitt lymphoma exclude ) Age 18 80 year ECOG performance status ≤ 2 receive multicycle Chemotherapy naive grade 3/4 neutropenia occur patient 's first cycle chemotherapy risk neutropenia ＞20 % without rhGCSF support Expected survival time≥3 month ; cNormal bone marrow function ( absolute neutrophil count ≥1.5 × 109/L ; platelet count ≥ 80 × 109/L ) Liver function : transaminase≤2.5× upper limit normal value，bilirubin≤2.5×upper limit normal value ; serum creatinine≤2×upper limit normal value ; Patients severe complication severe infection ; Invasion central nervous system ; Patients severe visceral organ dysfunction , heart block , myocardial infarction within 6 month ; Prior bone marrow stem cell organ transplantation patient severe allergic constitution , allergic Escherichia coli product ; 5 . Patients participate clinical study within 4 week ; Pregnancy , lactation Other patient suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lymphomas Non-Hodgkin 's B-Cell</keyword>
	<keyword>Lymphomas Non-Hodgkin 's T-Cell</keyword>
	<keyword>PEG-rhG-CSF</keyword>
	<keyword>Neutropenia</keyword>
</DOC>